• Rosacea

Mirvaso Generic Name & Formulations

General Description

Brimonidine tartrate 0.33%; topical gel; contains propylene glycol.

Pharmacological Class

Alpha-2 agonist.

How Supplied

Gel—30g (tube or pump), 45g (tube)

Generic Availability


Mirvaso Indications


Persistent (nontransient) facial erythema of rosacea.

Mirvaso Dosage and Administration


≥18yrs: apply a pea-sized amount once daily to each of the five areas of the face (forehead, chin, nose, each cheek); spread gel smoothly and evenly in a thin layer. Wash hands after use.


<18yrs: not established.

Mirvaso Contraindications

Not Applicable

Mirvaso Boxed Warnings

Not Applicable

Mirvaso Warnings/Precautions


Not for oral, ophthalmic, or intravaginal use. Avoid eyes, lips, irritated skin, or open wounds. Depression. Cerebral or coronary insufficiency. Raynaud's phenomenon. Orthostatic hypotension. Thrombangiitis obliterans. Scleroderma. Sjögrens syndrome. Severe or unstable cardiovascular disease. Pregnancy (Cat.B). Nursing mothers: not recommended.

Mirvaso Pharmacokinetics

See Literature

Mirvaso Interactions


Caution with beta-blockers, other antihypertensives, cardiac glycosides. Consider possibility of additive effects with CNS depressants (eg, alcohol, barbiturates, opiates, sedatives, anesthetics). Concomitant MAOIs may affect the metabolism and uptake of circulating amines; caution.

Mirvaso Adverse Reactions

Adverse Reactions

Erythema, flushing, burning sensation, contact dermatitis; systemic adverse reactions (eg, bradycardia, hypotension, dizziness), local vasomotor reactions (eg, pallor and excessive whitening, hypersensitivity [discontinue if significant]).

Mirvaso Clinical Trials

See Literature

Mirvaso Note

Not Applicable

Mirvaso Patient Counseling

See Literature